
-
Where Are They Now? Caribou Biosciences8/5/2024
Caribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.
-
GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 20258/1/2024
PwC's Medical Cost Trend: Behind The Numbers 2025 report offers details on the key 'inflators' and 'deflators' impacting medical spending next year. The key inflator? You guessed it, weight loss drugs.
-
Reading The Room In Oncology Drug Development7/11/2024
Oral conversations with the FDA about trial design and protocol can lead to questions, and answers, that help drug developers avoid costly surprises and misunderstandings.
-
Cash Needed For Phase 3 Celiac Drug Development6/28/2024
Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.
-
Companies To Watch: Volastra Therapeutics6/26/2024
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
Ten Years In, Project Data Sphere Is Snowballing6/21/2024
Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.
-
Partnering To Address 'Huge' Opportunities In Women's Health6/14/2024
Nonprofit research foundations can offer scientific expertise and support for biopharmaceutical drug development and clinical programs, helping companies improve new and existing drugs for women.
-
Where Are They Now? Otsuka5/30/2024
Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
-
Drug Discovery And Development, Powered By Physician Intelligence5/15/2024
For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.